Back To Schedule
Wednesday, June 26 • 8:00am - 9:15am
#313: Model Integrated Evidence as Pivotal Information for Drug Regulatory Decision Making: When, Where, and Why

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Basic
CE: ACPE 1.25 Knowledge UAN: 0286-0000-19-654-L04-P; CME 1.25; IACET 1.25; RN 1.25

The use of advanced quantitative methods and computational modeling has become part of modern drug development and assessment. Model Integrated Evidence (MIE) is an approach for generating evidence of bioequivalence via modeling and simulation.

Learning Objectives

Identify the core modeling and simulation capabilities (PBPK and QCP) that a generic drug manufacturer must posses; Evaluate lessons learned from the use of a model informed drug development process for new drugs, and apply common processes to generic drug development programs; Define and prepare for the future use of model informed evidence (MIE) in a generic drug submission and identify the value.


Liang Zhao, PhD


Industry Update
Michael A. Eldon, PhD, RPh

FDA Update From New Drugs Perspective
Yaning Wang, PhD

FDA Update from Generic Drugs Perspective
Liang Zhao, PhD

avatar for Yaning Wang

Yaning Wang

Director, Division of Pharmacometrics, OCP, OTS, CDER, FDA
Dr. Yaning Wang is the Director of the Division of Pharmacometrics in the Office of Clinical Pharmacology at FDA. Before joining FDA, Dr. Wang received his Ph.D. in Pharmaceutics and master’s degree in Statistics from the University of Florida from 1999 to 2003. He also obtained... Read More →

Liang Zhao

Director, Division of Quantitative Methods and Modeling, OGD, CDER, FDA
Dr. Liang Zhao has been serving as Director of the Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards (ORS) in Office of Generic Drugs, CDER since 2015. He initially joined FDA as a clinical pharmacology reviewer in the Office of Clinical Pharmacology... Read More →
avatar for Michael Eldon

Michael Eldon

Expert Consultant, NDA Partners LLC
Dr. Eldon has more than 37 years of experience in clinical pharmacology, pharmacokinetics/ pharmacodynamics and pharmacometrics in the pharmaceutical industry. He is an Expert Consultant at NDA Partners and as VP of Clinical Pharmacology at Nektar Therapeutics he was responsible for... Read More →

Wednesday June 26, 2019 8:00am - 9:15am
Room 6E San Diego Convention Center 111 W Harbor Drive, San Diego, CA 92101 USA